Synthesis of LY2623091

**Significance:** LY2623091 is a mineralocorticoid receptor antagonist that was of interest for the treatment of resistant hypertension. The kilogram-scale synthesis depicted features two sequential Heck reactions to construct the (E)-dihydrodibenzoo[b,e]oxepine ring system. Note the clean retention of stereochemistry in the conversion of (E)-F into bromoalkene (E)-G.

**Comment:** An investigation of the conversion of A into (E)-F through a one-pot, double Heck reaction revealed that the first Heck reaction (A → C) was fast and occurred at 60 °C whereas the second Heck reaction (C → (E)-F) required a much higher temperature (145 °C) owing to iodide acting as a catalyst poison. Better yields and stereoselectivity were obtained in the two-pot process shown.